← Back to Clinical Trials
Recruiting NCT06684249

Efficacy of Nerve Block Versus Botox in Chronic Migraine Management

Trial Parameters

Condition Chronic Migraine
Sponsor Zagazig University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 64
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2024-11-10
Completion 2025-05-10
Interventions
Nerve Block InjectionsBotulinum Toxin A

Brief Summary

The goal of this clinical trial is to determine whether nerve block injections (specifically, supratrochlear and greater occipital nerve injections) are as effective as Botulinum toxin A (Botox) injections in treating chronic migraine in adults. The main questions it aims to answer are: * Do nerve block injections reduce the number of monthly migraine days compared to baseline? * Are there any differences in the frequency of migraine-related symptoms between the nerve block and Botox treatment groups? * Which treatment leads to higher patient satisfaction and improved quality of life? Participants in this study will: * Receive either nerve block injections or Botox injections every 12 weeks. * Visit the clinic once every month for follow-ups and assessments. * Maintain a headache diary to record the frequency and severity of their migraines and any adverse effects experienced. * Researchers will compare the outcomes of the two groups to determine if one treatment is superior in terms of efficacy and patient satisfaction.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 to 65 years. * Diagnosis of chronic migraine, defined as having headaches on 15 or more days per month for more than three months, with at least 8 of those days meeting criteria for migraine. * Ability to provide informed consent and comply with study requirements. * No changes in prophylactic migraine medications in the last 3 months. Exclusion Criteria: * History of allergy or hypersensitivity to local anesthetics or Botulinum toxin. * Previous nerve block or Botox treatment within the last 6 months. * Significant comorbid psychiatric or neurological disorders that could interfere with study participation or evaluation. * Pregnancy or breastfeeding. * Contraindications to either treatment as per product labels.

Related Trials